In agreement with the title of a recent review (“Targeting transcription factors in cancer-from undruggable to reality” [147]), here we have outlined several strategies aimed at the design and delivery of FOSL1/Fra-1/AP-1-targeting molecules. The gene discussed is JUND; the disease is cancer.